From our sponsor Safeminds.
Earlier today the Natural News outlet released a letter from alleged CDC whistle-blower Bill Thompson to the Director of the CDC Julie Gerberding, MD dated February 2nd, 2004.
In the letter, Dr. Thompson refers to several news articles that appeared in the media during that time regarding CDC vaccine safety research and letters that Congressman Dave Weldon, M.D. sent to Dr. Gerberding regarding concerns related to the integrity of the scientists in the CDC’s National Immunization Program (NIP).
SafeMinds worked closely with Dr. Weldon for several years during his time in Congress. We shared with his staff FOIA documents SafeMinds received from the CDC and FDA regarding issues surrounding vaccine safety and the use of thimerosal in infant vaccines. These documents include emails from NIP employees, officials at CDC, officials from FDA, representatives from the American Academy of Pediatrics, and the vaccine industry, as well as the original transcripts of the Simpsonwood meeting.
Here is the letter referenced by Thompson where Congressman Weldon asks Dr. Gerberding about the upcoming publication of a CDC study regarding the use of thimerosal in infant vaccines and associations with adverse neurological disorders. Dr. Weldon’s concerns stemmed from earlier versions of the research obtained by SafeMinds which documented numerous statistically significant relations between exposure to thimerosal containing vaccines and ADD/ADHD, speech and language delays, tics, neurodevelopmental delays in general, misery disorder, sleep disorders, and autism.
According to these emails and documents, scientists were well aware of the harm that was occurring. An article appearing in the National Journal by Neil Munro titled, “Missing the Mercury Menace,” which Bill Thompson also references in his letter to Dr. Gerberding, outlines the manipulations made to the VSD thimerosal data in an effort to reduce the statistically significant adverse neurological outcomes. Read the full post at the Safeminds site here.